Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Rocha Lima CM, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda JC, Wallmark J, Portera C, Raja R, Stern H, Royer-Joo S, Amler LC.

Cancer Invest. 2012 Dec;30(10):727-31. doi: 10.3109/07357907.2012.732163. Epub 2012 Oct 12.

PMID:
23061802
2.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group..

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

3.

Scleromyxedema: successful treatment of cutaneous and neurologic symptoms.

Nieves DS, Bondi EE, Wallmark J, Raps EC, Seykora JT.

Cutis. 2000 Feb;65(2):89-92.

PMID:
10696560
4.

Tamoxifen's impact on the management of breast cancer: the oncologist's perspective.

Glick JH, Aviles VM, Wallmark J.

Oncology (Williston Park). 1997 Feb;11(2 Suppl 1):49-54. Review.

Supplemental Content

Loading ...
Support Center